Treatment of endometriosis with a delayed release preparation of the agonist D-Trp6-luteinizing hormone-releasing hormone: long-term follow-up in a series of 50 patients**Supported in part by Ipsen-Biotech, Paris, France.

1990 ◽  
Vol 53 (3) ◽  
pp. 401-406 ◽  
Author(s):  
Jean-Rene Zorn ◽  
Jane Mathieson ◽  
Francisco Risquez ◽  
Ana Maria Comaru-Schally ◽  
Andrew V. Schally
2009 ◽  
Vol 20 (2) ◽  
pp. 127-132 ◽  
Author(s):  
Neşe Colak Ozbey ◽  
Yersu Kapran ◽  
Alp Bozbora ◽  
Yeşim Erbil ◽  
Cemil Tascioglu ◽  
...  

1989 ◽  
Vol 142 (5) ◽  
pp. 1235-1238 ◽  
Author(s):  
Andrea U. Decensi ◽  
Domenico Guarneri ◽  
Paola Marroni ◽  
Liborio Di Cristina ◽  
Michela Paganuzzi ◽  
...  

1977 ◽  
Vol 74 (2) ◽  
pp. 291-296 ◽  
Author(s):  
H. M. FRASER ◽  
J. SANDOW

Immunization against luteinizing hormone releasing hormone (LH-RH) in adult male rats produced a progressive decline in LH and FSH in the circulation to low or non-detectable levels. d-Serine-tertiary-butyl6,des-glycine-NH210 LH-RH ethylamide is an analogue of LH-RH having highly active LH-RH properties in the normal rat. Because it is also immunologically different from LH-RH it can stimulate gonadotrophin release from the anterior pituitary gland of rats immunized against LH-RH without interference from the antibody. The analogue stimulated LH and FSH release in rats 15 weeks after immunization against LH-RH when antibody titre was highest, and after long-term (35 weeks) immunization against LH-RH. d-Serine-tertiary-butyl6,des-glycine-NH210 LH-RH ethylamide and related analogues are therefore potentially useful for reversing the effects of immunization against LH-RH.


Sign in / Sign up

Export Citation Format

Share Document